Immunopharmacology: Anti-inflammatory therapy targeting transcription factors

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 237-245

  Pfeilschifter, Josef ^a   Mühl, Heiko ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Aspirin; Cyclosporin A; Gene expression; Gene therapy; Glucocorticoid; Immunopharmacology; Inflammation; Recombinant cytokine; Salicylate; Tacrolismus; Transcription factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; TACROLIMUS; TRANSCRIPTION FACTOR;

AUTOIMMUNE DISEASE; GENE THERAPY; HUMAN; IMMUNOPHARMACOLOGY; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0345517955     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00361-1     Document Type: Article

References (99)

1. Abraham E., Glauser M.P., Butler T., Garbino J., Gelmont D., Laterre P.F., Knudsk K., Bruining H.A., Otto C., Tobin E., Zwingelstein C., Lesslauer W., Leighton A. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group. JAMA. 277:1997;1531-1538.
2. Arend W.P., Malyak M., Guthridge C.J., Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16:1998;27-55.
3. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 270:1995;286-290.
4. Baeuerle P.A. Pro-inflammatory signaling: last pieces in the NF-κB puzzle? Curr. Biol. 8:1998;R19-R22.
5. Bakker A., Joosten L.A., Arntz O.J., Helsen M.M.A., Bendele A.M., van de Loo F.A.J., van den Berg W.B. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 5:1997;893-900.
6. Ballow M., Nelson R. Immunopharmacology, immunomodulation and immunotherapy. JAMA. 278:1997;2008-2017.
7. Barnes P.J., Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. 14:1993;436-441.
8. Bates D.W., Sands K., Miller E., Lanken P.N., Hibberd P.L., Graman P.S., Schwartz J.S., Kahn K., Snydman D.R., Parsonnet J., Moore R., Black E., Johnson B.L., Jha A., Platt R. Predicting bacteremia in patients with sepsis syndrome. Academic medical center consortium sepsis project working group. J. Infect. Dis. 17:1997;1538-1551.
9. Berkman N., John M., Roesems G., Jose P.J., Barnes P.J., Chung K.F. Differential sensitivities in human blood monocytes and alveolar macrophages. J. Immunol. 155:1995;4412-4418.
10. Bessis N., Boissier M.-C., Ferrara P., Blankenstein T., Fradelizi D., Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur. J. Immunol. 26:1996;2399-2403.
11. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1991;1549-1555.
12. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., Watt I., Williams B., Aitchison R., McCabe D., Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:1998;2196-2204.
13. Briehl M.M., Flomerfelt F.A., Wu X.P., Miesfeld R.L. Transcriptional analyses of steroid-regulated gene networks. Mol. Endocrinol. 4:1990;287-294.
14. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F.H., Winkler H. Glucocorticoid mediated repression of NF-κB activity in endothelial cells does not involve induction of IκB synthesis. J. Biol. Chem. 171:1996;19612-19616.
15. Bruder J.T., Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and includes interleukin-8 expression. J. Virol. 71:1997;398-404.
16. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., Mercier J.C., Offenstadt G., Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 274:1995;968-974.
17. Caelles C., Ganzalez Sancho J.M., Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11:1997;3351-3364.
18. Cain B.S., Meldrum D.R., Harken A.H., McIntyre R.C. Jr. The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J. Am. Coll. Surg. 186:1998;337-350.
19. Caldenhoven E., Liden J., Wissink S., Van de Stolpe A., Raaijmakers J., Koendermann L.et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids. Mol. Endocrinol. 9:1995;401-412.
20. Cato A.C.B., Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. BioEssays. 18:1996;371-378.
21. Clesham G.J., Adam P.J., Proudfoot D., Flynn P.D., Efstathiou S., Weissberg P.L. High adenoviral loads stimulate NFκB-dependent gene expression in human vascular smooth muscle cells. Gene Ther. 5:1998;174-189.
22. Cope A.P. Regulation of autoimmunity by proinflammatory cytokines. Curr. Opin. Immunol. 10:1998;669-676.
23. Dalman F.C., Scherrer L.C., Taylor L.P., Akil H., Pratt W.B. Localisation of the 90-kDa heat shock protein-binding site within the hormone-binding domain of the glucocorticoid receptor by peptide competition. J. Biol. Chem. 266:1991;3482-3490.
24. DeWitt D.L., Meade E.A. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-2 isozymes. Arch. Biochem. Biophys. 306:1993;94-102.
25. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
26. Dinarello C.A., Gelfand J.A., Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 269:1993;1829-1835.
27. Dinarello C.A., Novick D., Puren A.J., Fantuzzi G., Shapiro L., Mühl H., Yoon D.-Y., Reznikov L.L., Kim S.-H., Rubinstein M. Overview of interleukin-18: more than an interferon-γ inducing factor. J. Leukocyte Biol. 63:1998;658-664.
28. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Buresh C.M., Norton J.A. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α J. Immunol. 149:1992;1666-1670.
29. Eigler A., Sinha B., Hartmann G., Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol. Today. 10:1997;487-492.
30. Evans C.H., Ghivizzani S.C., Robbins P.D. Blocking cytokines with genes. J. Leukocyte Biol. 64:1998;55-61.
31. Evans C.H., Ghivizzani S.C., Kang R., Muzzonigro T., Wasko M.C., Herndon J.H., Robbins P.D. Gene therapy for rheumatic diseases. Arthritis Rheum. 42:1999;1-16.
32. Firestein G.S., Zvaifler N.J. Anticytokine therapy in rheumatoid arthritis. N. Engl. J. Med. 337:1997;195-197.
33. Fisher C.J. Jr., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., Abraham E., Schein R.M.H., Benjamin E. N. Engl. J. Med. 334:1996;1697-1702.
34. Frantz B., Nordby, Bren G., Steffan N., Paya C.V., Kincaid R.L., Tocci M.J., O'Keefe S.J.O., O'Neill E.A.O. Calcineurin acts in synergy with PMA to inactivate IκB/MAD3, an inhibitor of NF-κB. EMBO J. 13:1994;861-870.
35. Fuchs A.C., Granovitz E.V., Shapiro L., Vannier E., Lonnemann G., Angel J.B., Kennedy J.S., Rabson A.R., Radwanski E., Affrime M.B., Cutler D.L., Grint P.C., Dinarello C.A. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin. Immunol. 16:1996;291-303.
36. Ghivizzani S.C., Kang R., Muzzonigro T., Whalen J., Watkins S.C., Herndon J.H.et al. Gene therapy for arthritis-treatment of the first three patients. Arthritis Rheum. 40:1997;223.
37. Ghivizzani S.C., Lechman E.R., Kang R., Tio C., Kollis J., Evans C.H., Robbins P.D. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad. Sci. U.S.A. 95:1998;4613-4618.
38. Gottesfeld J.M., Neely L., Trauger J.W., Baird E.E., Devan P.B. Regulation of gene expression by small molecules. Nature. 387:1997;202-205.
39. Gottschalk U., Chan S. Somatic gene therapy. Present situation and future perspective. Arzneim.-Forsch./Drug Res. 48:1998;1111-1120.
40. Granowitz E.V., Porat R., Mier J.W., Pribble J.P., Stiles D.M., Bloedow D.C., Catalano M.A., Wolff S.M., Dinarello C.A. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 4:1992;353-360.
41. Guido E.C., Delorme E.O., Clemm D.L., Stein R.B., Rosen J., Miner J.N. Determinants of promoter-specific activity by glucocorticoid receptor. Mol. Endocrinol. 10:1996;1178-1190.
42. Heck S. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13:1994;4087-4095.
43. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:1999;530-534.
44. Isomaki P., Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med. 29:1997;499-507.
45. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C., Gebel S., Ponta H., Herrlich P. Antitumor promotion and anti-inflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 62:1990;1189-1204.
46. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.C., Heyman R.A., Rose D.W., Glass C.K., Rosenfeld M.G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
47. Knudsen P.J., Dinarello C.A., Strom T.B. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclicadenosine monophosphate. J. Immunol. 137:1986;3189-3194.
48. Kopp E., Sankar G. Inhibition of NF-κB binding by sodium salicylate and aspirin. Science. 265:1994;956-959.
49. Kunz D., Walker G., Eberhardt W., Nitsch D., Pfeilschifter J. Interleukin-1β-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. Biochem. Biophys. Res. Commun. 216:1995;438-446.
50. Kunz D., Walker G., Eberhardt W., Pfeilschifter J. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1β-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc. Natl. Acad. Sci. U.S.A. 93:1996;255-259.
51. Lalani I., Bhol K., Ahmed A.R. Interleukin-10: biology, role in inflammation and autoimmunity. Ann. Allergy, Asthma, Immunol. 79:1997;469-483.
52. Le C.H., Nicolson A.G., Morales A., Sewell K.L. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene. Arthritis Rheum. 40:1997;1662-1669.
53. Liden J., Delaunay F., Rafter I., Gustafsson J., Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 272:1997;21467-21472.
54. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today. 14:1993;290-295.
55. Makarov S.S., Olsen J.C., Johnston W.N., Anderle S.K., Brown R.R., Baldwin A.S. Jr., Haskill J.S., Schwab J.H. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc. Natl. Acad. Sci. U.S.A. 93:1996;402-406.
56. Marienfeld R., Neumann M., Chuvpilo S., Escher C., Kneitz B., Avots A. Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors, but not with the processing of p105/NF-κB1 in T-cells. Eur. J. Immunol. 27:1997;1601-1609.
57. May M.J., Gosh S. Signal transduction through NF-κB. Immunol. Today. 19:1998;80-88.
58. McEwan I.J., Wright A.P.H., Gustafsson J.-A. Mechanism of gene expression by the glucocorticoid receptor: role of protein-protein interactions. BioEssays. 19:1997;153-160.
59. Meyer S., Kohler N.G., Joly A. Cyclosporin A is an uncompetitive inhibitor of proteosome activity and prevents NF-κB activation. FEBS Lett. 413:1997;354-358.
60. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:1997;141-147.
61. 2 gene expression by interleukin 1 and forskolin in rat mesangial cells. FEBS Lett. 301:1992;190-194.
62. Mühl H., Kunz D., Rob P., Pfeilschifter J. Cyclosporin derivatives inhibit interleukin 1β induction of nitric oxide synthase in renal mesangial cells. Eur. J. Pharmacol. 249:1993;95-100.
63. Novick D., Kim S.-H., Fantuzzi G., Reznikov L.L., Dinarello C.A., Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immmunity. 10:1999;127-136.
64. Okamura H., Tsutsui H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K., Akita K., Namba M., Tanabe F., Konishi K., Fukuda S., Kurimoto M. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 378:1995;88-91.
65. Opal S.M., Fisher C.J., Dhainaut J.-F., Vincent J.-L., Brase R., Lowry S.F., Sadoff J.C., Slotman G.J., Levy H., Balk R.A., Shelly M.P., Pribble J.P., LaBrecque J.F., Lookabaugh J., Donovan H., Dubin H., Baughman R., Norman J., Demaria E., Matzel K., Abraham E., Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 25:1997;1115-1124.
66. Otani K., Nita I., Macaulay W., Gerorgescu H.I., Robbins P.D., Evans C.H. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J. Immunol. 156:1996;3558-3562.
67. Owens G.P., Hahn W.E., Cohen J.J. Identification of mRNAs associated with programmed cell death in immature thymocytes. Mol. Cell Biol. 11:1991;4177-4188.
68. Papavassiliou A.G. Transcription-factor-modulating agents: precision and selectivity in drug design. Mol. Med. Today. 4:1998;358-366.
69. Peterson M.G., Baichwal V.R. Transcription factor based therapeutics: drugs of the future? TIBTECH. 11:1993;11-18.
70. Pfahl M. Nuclear receptor/AP-1 interaction. Endocrinol. Rev. 14:1993;651-658.
71. Pfeilschifter J., Schwarzenbach H. Interleukin 1 and tumor necrosis factor stimulate cGMP in rat renal mesangial cells. FEBS Lett. 273:1990;185-187.
72. 2 inhibits interleukin 1β-and tumour necrosis factor α-induction of nitric oxide synthase in rat renal mesangial cells. Biochem. Biophys. Res. Commun. 175:1991;372-379.
73. 2 synthesis in rat renal mesangial cells. Biochem. J. 270:1990;269-271.
74. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. 7:1996;1437-1446.
75. + human blood mononuclear cells. J. Clin. Invest. 101:1998;711-721.
76. Ray A., Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription of NF-κB and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 91:1994;752-756.
77. Reichardt H.M., Schütz G. Glucocorticoid signalling - multiple variations of a common theme. Mol. Cell. Endocrinol. 146:1998;1-6.
78. 2 in rat mesangial cells is prevented by dexamethasone. Biochem. Biophys. Res. Commun. 180:1991;46-52.
79. 2 in rat mesangial cells is prevented by transforming growth factor β2. J. Biol. Chem. 267:1992;8846-8851.
80. 2 activity and protein synthesis is blocked by dexamethasone in rat mesangial cells. FEBS Lett. 333:1993;339-343.
81. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-286.
82. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunology Today. 13:1992;136-142.
83. Schüle R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., Evans R.M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 62:1990;1217-1226.
84. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik E.Y., Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2869-2873.
85. Smith J.G., Walzem R.L., German J.B. Liposomes as agents of DNA transfer. Biochim. Biophys. Acta. 21:1993;327-340.
86. Stein C.A. Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. Chem. Biol. 3:1996;319-323.
87. Tetta C., Mariano F., Buades J., Ronco C., Wratten M.L., Camussi G. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. Am. J. Kidney Dis. 30:1997;S57-S65.
88. van der Meer J.W., Vogels M.T., Netea M.G., Kullberg B.J. Proinflammatory cytokines and treatment of disease. Ann. N.Y. Acad. Sci. 856:1998;243-251.
89. Vannier E., Miller L.C., Dinarello C.A. Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4076-4080.
90. Vannier E., de Waal Malefyt R., Salazar-Montes A., de Vries J.E., Dinarello C.A. Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood. 87:1996;3307-3315.
91. van Roon J.A.G., van Roy J.L.A.M., Gmelig-Meyling F.H.J., Lafeber F.P.J.G., Bijlsma J.W.J. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum. 39:1996;829-835.
92. Walker G., Pfeilschifter J., Kunz D. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in interferon (IFN)-γ-stimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation. J. Biol. Chem. 272:1997;16679-16687.
93. 2 in rat renal mesangial cells. Br. J. Pharmacol. 121:1997;787-793.
94. Wilckens T., de Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today. 18:1997;418-424.
95. Wissink S., van Heerde E.C., Schmitz M.L., Kalkhoven E., van der Burg B., Baeuerle P.A., van der Saag P.T. Distinct domains of the RelA NF-κB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J. Biol. Chem. 272:1997;22278-22284.
96. Wolkow P.P. Involvement and dual effects of nitric oxide in septic shock. Inflammation Res. 47:1998;152-166.
97. Yang Yen H.F., Chambard J.C., Sun Y.L., Smeal T., Schmidt T.J., Drouin J., Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 62:1990;1205-1215.
98. Yin M.-J., Yamamato Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β Nature. 396:1998;77-80.
99. Zilliacus J., Wright A.P., Carlstedt-Duke J., Gustafsson J.-A. Structural determinants of DNA-binding specificity by steroid receptors. Mol. Endocrinol. 9:1995;389-400.